Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair

Nuvation Bio Inc.

Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.
CEO David Hung appointed Chair of the Board; Robert Bazemore appointed Lead Independent Director.
Committee chairs set: Falberg (Audit), Vernon (Compensation), Bazemore (Nominating/Governance).
All five proposals passed: directors elected, KPMG ratified, executive compensation approved, conversion approved, adjournment approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.